Abstract
Aims: to study the role of rectal diclofenac in prevention of post-ErcP (endoscopic retrograde cholangiopancreatography) pancreatitis and its impact on severity of post-ErcP pancreatitis. Methods: We conducted a single centre, prospective, open labelled, randomized trial for evaluating the use of rectal diclofenac in prevention of post-ErcP pancreatitis in high risk patients. We assessed 526 patients given for ErcP for different indications. 400 patients were eligible for the study. those not fitting the high risk criteria and with acute pancreatitis were excluded. these patients were randomized in two groups, 200 patients received rectal diclofenac prior to or during the procedure while 200 patients received placebos. serum amylase was measured at 2 hr and 36 hr. PostErcP pancreatitis was defined as serum amylase > 3 times ULN associated with severe abdominal pain. severity was graded according to days of hospitalization and complications. results: 29 out of 400 (7.2%) patients developed post
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Hepatobiliary and Pancreatic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
